Matthias Eder

GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Development and Preclinical Evaluation of [²¹¹At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry

Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide

Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

A Day 14 Endpoint for Acute GVHD Clinical Trials

2-[18F]F-<i>p</i>-Aminobenzoic Acid Specifically Detects Infective Endocarditis in Positron Emission Tomography

The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

The utility of biomarkers in acute GVHD prognostication

Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

A Day 14 Endpoint for Acute Gvhd Clinical Trials

Supplementary Data from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

Movie S7 from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

Movie S6 from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

Data from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

Movie S1 from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

All Supplementary Tables, Figures and Methods from Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors

Movie S4 from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

Movie S5 from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

Movie S3 from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies